Advertisement

Bionanotechnology in Medicine

  • Young-Chul Lee
  • Ju-Young Moon
Chapter
  • 32 Downloads

Abstract

It should be recalled that the creation, control, and use of nano-scale structures, devices, and systems is the domain of nanotechnology and bionanotechnology deals with the diagnostic, therapeutic, and clinical applications of nanotechnology in biomedical, bioscience, and any subunit of health care for that matter. A key stage in health care is diagnosis as timely diagnosis can lead to the higher effectiveness of disease treatment, thus giving more positive outcomes and curtailed total costs. New technologies are necessary to speed the diagnostic processes and help the clinicians and scientists in the initiation of targeted treatments and in the monitoring of treatment responses. An important objective of medicine now is to exploit initial accomplishments and combining them with available technologies to identify the earliest signatures of fatal conditions, allowing us to provide immediate and specific interventions and monitor the condition progresses before chronic inflammation and malignancy happen. The improvement of diagnostic technologies can be supported by bionanotechnology, as a result of unique mechanical, chemical, electrical, and optical properties at nano-scale. Immediate benefits to the users can be presented by the development and use of tools in diagnostic field. The technologies of 1–100 nm size can assist in sensing or visualizing interactions with receptors, specific organelles, cytoskeletons, and nuclear components within the cells. They are expected to be able to migrate into monitoring the health condition by means of non-invasive methods in vivo. The growth in nanotechnology assists us in differentiating between abnormal and normal cells and detecting and quantifying minor amounts of signature molecules produced by the cells [1].

References

  1. 1.
    Papazoglou ES, Parthasarathy A. Bionanotechnology. Morgan & Claypool; 2007.Google Scholar
  2. 2.
    Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19:311–30.  https://doi.org/10.1096/fj.04-2747rev.CrossRefGoogle Scholar
  3. 3.
    Hayes ME, et al. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Therapy. 2005; 13: 646. doi: https://doi.org/10.1038/sj.gt.3302699.CrossRefGoogle Scholar
  4. 4.
    Cloninger MJ. Biological applications of dendrimers. Curr Opin Chem Biol. 2002;6:742–8.  https://doi.org/10.1016/S1367-5931(02)00400-3.CrossRefGoogle Scholar
  5. 5.
    Vercoutere W, et al. Rapid discrimination among individual DNA hairpin molecules at single-nucleotide resolution using an ion channel. Nat Biotechnol. 2001; 19, 248, doi: https://doi.org/10.1038/85696.CrossRefGoogle Scholar
  6. 6.
    Wang S, Zhao Z, Haque F, Guo P. Engineering of protein nanopores for sequencing, chemical or protein sensing and disease diagnosis. Curr Opin Biotechnol. 2018;51:80–9.  https://doi.org/10.1016/j.copbio.2017.11.006.CrossRefGoogle Scholar
  7. 7.
    Thomas H, et al. Nanopore sequencing as a rapidly deployable Ebola outbreak tool. Emerg Infect Dis J. 2016; 22, 331, doi: https://doi.org/10.3201/eid2202.151796.
  8. 8.
    Ashton PM, et al. MinION nanopore sequencing identifies the position and structure of a bacterial antibiotic resistance island. Nat Biotechnol. 2014; 33: 296. doi: https://doi.org/10.1038/nbt.3103.CrossRefGoogle Scholar
  9. 9.
    Garalde DR, et al. Highly parallel direct RNA sequencing on an array of nanopores. Nat Methods. 2018; 15, 201. doi: https://doi.org/10.1038/nmeth.4577.CrossRefGoogle Scholar
  10. 10.
    Wongsurawat T, et al. Rapid sequencing of multiple RNA viruses in their native form. Front Microbiol. 2019; 10: 260. doi: https://doi.org/10.3389/fmicb.2019.00260.
  11. 11.
    Chen M, McDaniel JR, Mackay JA, Chilkoti A. Nanoscale self-assembly for delivery of therapeutics and imaging agents. Technol Innov. 2011;13:5–25.  https://doi.org/10.3727/194982411X13003853539948.CrossRefGoogle Scholar
  12. 12.
    Allen M, et al. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Mgn Reson Med. 2005; 54: 807–12. doi: https://doi.org/10.1002/mrm.20614.CrossRefGoogle Scholar
  13. 13.
    Bhushan B. Encyclopedia of nanotechnology, 2012.Google Scholar
  14. 14.
    McLoughlin KS. Microarrays for pathogen detection and analysis. Brief Funct Genomics. 2011;10:342–53.  https://doi.org/10.1093/bfgp/elr027.CrossRefGoogle Scholar
  15. 15.
    Chen H, Li J. In Jang B. Rampal (ed) Microarrays: volume 1: synthesis methods. Humana Press, 2007. 411–436.Google Scholar
  16. 16.
    Huang D, Patel K, Perez-Garrido S, Marshall JF, Palma M. DNA origami Nanoarrays for multivalent investigations of Cancer cell spreading with Nanoscale spatial resolution and single-molecule control. ACS Nano. 2019;13:728–36.  https://doi.org/10.1021/acsnano.8b08010.CrossRefGoogle Scholar
  17. 17.
    Han M, Gao X, Su JZ, Nie S. Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nat Biotechnol. 2001;19:631–5.  https://doi.org/10.1038/90228.CrossRefGoogle Scholar
  18. 18.
    Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater. 2005;4:435–46.  https://doi.org/10.1038/nmat1390.ADSCrossRefGoogle Scholar
  19. 19.
    Mitchell P. Turning the spotlight on cellular imaging. Nat Biotechnol. 2001;19:1013–7.  https://doi.org/10.1038/nbt1101-1013.CrossRefGoogle Scholar
  20. 20.
    Michalet X, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005; 307, 538–544. doi: https://doi.org/10.1126/science.1104274.ADSCrossRefGoogle Scholar
  21. 21.
    Jaiswal JK, Simon SM. Potentials and pitfalls of fluorescent quantum dots for biological imaging. Trends Cell Biol. 2004;14:497–504.  https://doi.org/10.1016/j.tcb.2004.07.012.CrossRefGoogle Scholar
  22. 22.
    Lee CC, MacKay JA, Fréchet JMJ, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol. 2005;23:1517–26.  https://doi.org/10.1038/nbt1171.CrossRefGoogle Scholar
  23. 23.
    Yang H, Kao W. J. Dendrimers for pharmaceutical and biomedical applications. Journal of biomaterials science. Polymer Edition. 2006;17:3–19.  https://doi.org/10.1163/156856206774879171.CrossRefGoogle Scholar
  24. 24.
    Yan G-P, Hu B, Liu M-L, Li L-Y. Synthesis and evaluation of gadolinium complexes based on PAMAM as MRI contrast agents. J Pharm Pharmacol. 2005;57:351–7.  https://doi.org/10.1211/0022357055506.CrossRefGoogle Scholar
  25. 25.
    Chen Z, et al. The advances of carbon nanotubes in Cancer diagnostics and therapeutics. J Nanomater. 2017, 2017:13.  https://doi.org/10.1155/2017/3418932.ADSGoogle Scholar
  26. 26.
    Avti PK, et al. Detection, mapping, and quantification of single walled carbon nanotubes in histological specimens with photoacoustic microscopy. PloS One. 2012; 7, e35064, doi: https://doi.org/10.1371/journal.pone.0035064.ADSCrossRefGoogle Scholar
  27. 27.
    Perez JM, Josephson L, Weissleder R. Use of magnetic nanoparticles as nanosensors to probe for molecular interactions. Chem Bio Chem. 2004;5:261–4.  https://doi.org/10.1002/cbic.200300730.CrossRefGoogle Scholar
  28. 28.
    Bogdanov A, Matuszewski L, Bremer C, Petrovsky A, Weissleder R. Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets. Mol Imaging. 2002;1:153.  https://doi.org/10.1162/15353500200200001.CrossRefGoogle Scholar
  29. 29.
    Anzai Y. Superparamagnetic Iron oxide nanoparticles: nodal metastases and beyond. Top Magn Reson Imaging. 2004;15:103–11.  https://doi.org/10.1097/01.rmr.0000130602.65243.87.CrossRefGoogle Scholar
  30. 30.
    Harisinghani MG, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003; 348: 2491–9. doi: https://doi.org/10.1056/NEJMoa022749.CrossRefGoogle Scholar
  31. 31.
    Lee H, et al. High-performance nanogap electrode-based impedimetric sensor for direct DNA assays. Biosens Bioelectr. 2018; 118: 153–9, doi: https://doi.org/10.1016/j.bios.2018.07.050.CrossRefGoogle Scholar
  32. 32.
    Hartung G, et al. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in Cancer patients. Clin Cancer Res. 1999;5:753–9.Google Scholar
  33. 33.
    Kim J-G, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate. the ability to activate the glucagon-like peptide 1 receptor in vivo. 2003; 52:751–9. doi: https://doi.org/10.2337/diabetes.52.3.751.CrossRefGoogle Scholar
  34. 34.
    Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132:171–83.  https://doi.org/10.1016/j.jconrel.2008.05.010.CrossRefGoogle Scholar
  35. 35.
    Mao W, et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 2004; 64: 781–8. doi: https://doi.org/10.1158/0008-5472.can-03-1047.CrossRefGoogle Scholar
  36. 36.
    Cattel L, Ceruti M, Dosio F. From conventional to Stealth liposomes: a new frontier in Cancer chemotherapy. J Chemother. 2004;16:94–7.  https://doi.org/10.1179/joc.2004.16.Supplement-1.94.CrossRefGoogle Scholar
  37. 37.
    Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004; 15: 440–9. doi: https://doi.org/10.1093/annonc/mdh097.CrossRefGoogle Scholar
  38. 38.
    Mastrobattista E, Koning GA, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev. 1999;40:103–27.  https://doi.org/10.1016/S0169-409X(99)00043-5.CrossRefGoogle Scholar
  39. 39.
    Discher DE, Ahmed F. Polymersomes. Annu Rev Biomed Eng. 2006;8:323–41.  https://doi.org/10.1146/annurev.bioeng.8.061505.095838.CrossRefGoogle Scholar
  40. 40.
    Peppas NA, Hilt JZ, Khademhosseini A, Langer R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv Mater. 2006;18:1345–60.  https://doi.org/10.1002/adma.200501612.CrossRefGoogle Scholar
  41. 41.
    Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007;59:645–66.  https://doi.org/10.1016/j.addr.2007.05.012.CrossRefGoogle Scholar
  42. 42.
    Choucha Snouber L, et al. Metabolomics-on-a-chip of hepatotoxicity induced by anticancer drug flutamide and its active metabolite hydroxyflutamide using HepG2/C3a microfluidic biochips. Toxicol Sci. 2012; 132: 8–20. doi: https://doi.org/10.1093/toxsci/kfs230.CrossRefGoogle Scholar
  43. 43.
    Hirsch LR, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A. 2003; 100: 13549–54. doi: https://doi.org/10.1073/pnas.2232479100.ADSCrossRefGoogle Scholar
  44. 44.
    Saito R, et al. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol. 2005; 196: 381–9. doi:10.1016/j.expneurol.2005.08.016.CrossRefGoogle Scholar
  45. 45.
    Tsourkas A, et al. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjug Chem. 2005; 16: 576–81. doi: https://doi.org/10.1021/bc050002e.CrossRefGoogle Scholar
  46. 46.
    Stendahl J. C. & Sinusas, A. J. nanoparticles for cardiovascular imaging and therapeutic delivery, part 1: compositions and features. Journal of nuclear medicine: official publication. Society of Nuclear Medicine. 2015;56:1469–75.  https://doi.org/10.2967/jnumed.115.160994.CrossRefGoogle Scholar
  47. 47.
    Jeong W-J, et al. Peptide-nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms? Nano Convergence. 2018; 5: 38. doi: https://doi.org/10.1186/s40580-018-0170-1.
  48. 48.
    Fan Z, et al. Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy. Nat Commun. 2018; 9: 2605. doi: https://doi.org/10.1038/s41467-018-04763-y.
  49. 49.
    Fan Z, Sun L, Huang Y, Wang Y, Zhang M. Bioinspired fluorescent dipeptide nanoparticles for targeted cancer cell imaging and real-time monitoring of drug release. Nat Nanotechnol. 2016;11:388–94.  https://doi.org/10.1038/nnano.2015.312.ADSCrossRefGoogle Scholar
  50. 50.
    Zhu J, Fu F, Xiong Z, Shen M, Shi X. Dendrimer-entrapped gold nanoparticles modified with RGD peptide and alpha-tocopheryl succinate enable targeted theranostics of cancer cells. Colloids Surf B: Biointerfaces. 2015;133:36–42.  https://doi.org/10.1016/j.colsurfb.2015.05.040.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Young-Chul Lee
    • 1
  • Ju-Young Moon
    • 2
  1. 1.Department of BioNano TechnologyGachon UniversitySeongnam-siRepublic of Korea
  2. 2.Department of Beauty Design ManagementHansung UniversitySeoulRepublic of Korea

Personalised recommendations